Chemir Launches IQsynthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Chemir Launches IQsynthesis


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Chemir Launches IQsynthesis

Patricia Van Arnum

St. Louis, MO (Sept. 15)—Chemir Analytical Services (Maryland Heights, MO, www.chemir.com) has launched IQsynthesis (www.IQsynthesis.com), formerly known as Gateway Chemical Technology, Inc. Chemir acquired Gateway Chemical Technology, which provides custom synthesis and process development services, in May 2006.

“Clients have been requesting synthetic chemistry services, and we sought an acquisition to best fill this need,” explains Shri Thanedar, CEO of Chemir Analytical Services. 

IQsynthesis offers synthesis services for pharmaceutical intermediates; bioorganic compounds; and specialty, fine, and agrochemicals. Other services include synthesis of analytical standards, metabolites, tox lot batches, stable isotope-labeled compounds, intermediates, custom surfactants, combinational platforms, extraction and purification of natural products, and process development. Plans are underway to expand laboratory space and staff as well as develop infrastructure and systems for CGMP-regulated synthesis.

The Chemir group of companies include IQsynthesis; Chemir Analytical Services; Azopharma, a pharmaceutical contract service provider; and CAS-MI, a laboratory serving the paints, coatings, and polymer industries. Total sales for the company are expected to reach $24 million in 2006, with an anticipated goal of reaching $50 million by 2009.

ADVERTISEMENT

RELATED CONTENT
Virtual Product Development Offers Cost Savings
Pfizer Plans Additional Cost Cutting
AnorMED accepts Genzyme's Offer of US $13.50 a Share
PhRMA Names New Chairman
Merck KGaA to Acquire Majority Stake in Serono for $13.3 Billion
post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters
Subscribe:Check the box next to each newsletter you wish to subscribe for:
| Weekly
| Monthly
| Monthly | Weekly
 Name:
 E-mail:

Survey
At this month's AAPS Annual Meeting & Exposition, several graduate students were awarded as young innovators. What are your thoughts on innovation and the next generation?
We need more young innovators and more students enrolling in pharma science programs
Our industry has just the right mix of young and old to keep innovation going
Age is irrelevant when it comes to innovation
We need more young innovators and more students enrolling in pharma science programs
25%
Our industry has just the right mix of young and old to keep innovation going
16%
Age is irrelevant when it comes to innovation
59%
View Results
Jim MillerOutsourcing OutlookJim Miller Facing Reality
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advancing Chiral Chemistry in API Synthesis
Faiz kermaniSpotlightFaiz Kermani Demographic time bomb
Rx-360 Takes on Europe, Talks to PharmTech in Podcast Series
Sanctions, Not Barcodes
Vaccines Finding Their Way in Novel Applications
Genzyme’s Friday the 13th
DTCA: Beneficial or Harmful?
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here